06Jun 2022
Genomic biomarkers to guide precision radiotherapy in prostate cancer

Genomic biomarkers to guide precision radiotherapy in prostate cancer

Our ability to prognosticate the clinical course of patients with cancer has historically been limited to clinical, histopathological, and radiographic features. However, it has long been clear that these data alone do not adequately capture the heterogeneity and breadth of disease trajectories experienced by patients. The advent of efficient genomic sequencing has led to a revolution in cancer care as we try to understand and personalize treatment specific to patient clinical‐genomic phenotypes. Herein the study review selects literature surrounding the use of tumor genomics within the management of prostate cancer, explicitly leaning toward analytically validated and clinically tested genomic biomarkers utilized in radiotherapy and adjunctive therapies given with radiotherapy.

  • #urology

Like

Save

Share